CHE: Key Enzyme for Maintaining Cholesterol Balance (P45367)

Target Name: Cholesterol esterase

NCBI ID: P45367

Cholesterol esterase

Other Name(s): CHE | CE | Cholesterol esterase

CHE: Key Enzyme for Maintaining Cholesterol Balance

Cholesterol esterase (CLE) is a protein that is synthesized in the liver and is involved in the metabolism of cholesterol. It is one of the three main forms of cholesterol in the body, along with low-density lipoprotein (LDL) and high-density lipoprotein (HDL). CLE is a key enzyme that breaking down LDL cholesterol, which is the primary cause of heart disease and stroke.

CLE is a member of the family of enzymes known as lipidases, which are responsible for breaking down lipids such as cholesterol and fat. The nonspecified subtype of cholesterol esterase (CHE) is a specific type of enzyme that is involved in the breakdown of LDL cholesterol.

CHE is a transmembrane protein that is expressed in the liver, heart, and other tissues. It is a potent enzyme that is involved in the metabolism of LDL cholesterol, breaking it down into smaller molecules that can be either used for energy or stored as fat . CHE is also involved in the synthesis of other lipids, including triglycerides and fatty acids.

CHE is a critical enzyme in the body that helps maintain proper levels of cholesterol in the blood. High levels of LDL cholesterol in the blood are a major risk factor for the development of heart disease and stroke, while low levels of HDL cholesterol are associated with an increased risk of heart disease. CHE helps to keep the balance between these two forms of cholesterol, ensuring that the body has the right amount of each to maintain good health.

The nonspecified subtype of CHE is a gene that is located on chromosome 11. It is a single gene that encodes the protein CHE. CHE is a member of the superfamily of ATP-dependentases, which are a group of enzymes that use ATP to perform a variety of functions, including breaking down lipids.

CHE is expressed in many different tissues in the body, including the liver, heart, and kidneys. It is a key enzyme in the liver, where it is involved in the breakdown of LDL cholesterol. The liver is the primary site of cholesterol synthesis in the body, and it is responsible for exporting most of the cholesterol produced to the rest of the body. CHE is also involved in the synthesis of other lipids, including triglycerides and fatty acids.

CHE is a critical enzyme in the body that helps maintain proper levels of cholesterol in the blood. High levels of LDL cholesterol in the blood are a major risk factor for the development of heart disease and stroke, while low levels of HDL cholesterol are associated with an increased risk of heart disease. CHE helps to keep the balance between these two forms of cholesterol, ensuring that the body has the right amount of each to maintain good health.

The nonspecified subtype of CHE is a gene that is located on chromosome 11. It is a single gene that encodes the protein CHE. CHE is a member of the superfamily of ATP-dependent enzymes, which are a group of enzymes that use ATP to perform a variety of functions, including breaking down lipids.

CHE is expressed in many different tissues in the body, including the liver, heart, and kidneys. It is a key enzyme in the liver, where it is involved in the breakdown of LDL cholesterol. The liver is the primary site of cholesterol synthesis in the body, and it is responsible for exporting most of the cholesterol produced to the rest of the body. CHE is also involved in the synthesis of other lipids, including triglycerides and fatty acids.

One of the most promising aspects of CHE is its potential as a drug target. CHE has been shown to be involved in a variety of cellular processes, including the regulation of cellular signaling pathways and the metabolism of lipids. It is also involved in the production of other lipids, including triglycerides and fatty acids.

CHE has also been shown to be involved in the regulation of cellular signaling pathways. It is a key enzyme in the pathway that regulates the production of low-density lipoprotein (LDL) cholesterol, which is a major risk factor for the development of heart disease and stroke. By targeting CHE with drugs, researchers may be able to reduce the production of LDL cholesterol in the body and lower the risk of heart disease and stroke.

Another promising aspect of CHE is its potential as a biomarker. CHE is a protein that is expressed in many different tissues in the body, including the liver, heart, and kidneys. It is a key enzyme in the liver, where it is involved in the breakdown of LDL cholesterol. The levels of CHE in these tissues can be used as a marker for the health of these tissues, providing insight into the overall health of the body.

In conclusion, cholesterol esterase (CLE) is a protein that is involved in the metabolism of cholesterol in the body. It is a critical enzyme that helps maintain proper levels of cholesterol in the blood and is a potential drug target. The nonspecified subtype of CHE is a gene that is located on chromosome 11 and encodes the protein CHE. CHE is expressed in many different tissues in the body, including the liver, heart, and kidneys, and is involved in the breakdown of LDL cholesterol. By targeting CHE with drugs , researchers may be able to reduce the production of LDL cholesterol in the body and lower the risk of heart disease and stroke. It is also a potential biomarker that can provide insight into the overall health of the body.

Protein Name: Cholesterol Esterase (nonspecified Subtype)

The "Cholesterol esterase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Cholesterol esterase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets